How to Get Armour Thyroid in Iowa: Prescriptions, Telehealth, and Pharmacies

Prescription access and medication affordability image for How to Get Armour Thyroid in Iowa: Prescriptions, Telehealth, and Pharmacies

At a glance

  • Drug / Armour Thyroid (natural desiccated thyroid, porcine-derived), manufactured by Allergan
  • Indication / Hypothyroidism (primary, secondary, or post-thyroidectomy)
  • Prescription required / Yes. Schedule: prescription-only, not controlled
  • Telehealth prescribing in Iowa / Yes. Iowa law permits telehealth Rx after a valid patient-provider relationship is established
  • Typical starting dose / 30 mg (½ grain) once daily on an empty stomach, titrated every 4-8 weeks
  • Labs required before prescribing / TSH, free T4, free T3; CBC and lipid panel often added at first visit
  • Iowa Medicaid coverage / Not covered; most commercial plans require prior authorization
  • Compounding option / Yes. Iowa-licensed 503A compounding pharmacies may prepare desiccated thyroid preparations

What Is Armour Thyroid and Why Do Iowa Patients Request It?

Armour Thyroid is a prescription porcine-derived desiccated thyroid extract that supplies both thyroxine (T4) and triiodothyronine (T3) in a roughly 4:1 ratio by weight. Many patients who have not reached symptomatic relief on levothyroxine monotherapy ask their providers about adding T3 or switching to a combination product like Armour Thyroid. The FDA has recognized Armour Thyroid since 1939, and the current prescribing label is maintained by Allergan (FDA label).

A 2013 cross-over trial by Hoang et al. in the Journal of Clinical Endocrinology and Metabolism (N=70) found that 49% of participants preferred desiccated thyroid extract over levothyroxine, and the desiccated thyroid group lost an average of 4 pounds more over 16 weeks (pubmed.ncbi.nlm.nih.gov/23539727). That single trial does not override the larger evidence base supporting levothyraxine as first-line therapy, but it does explain the sustained patient interest in Armour Thyroid across Iowa and nationally.

The American Thyroid Association's 2014 guidelines (Garber et al.) state that "combination T4 and T3 therapy may be beneficial in a subset of hypothyroid patients," acknowledging that patient preference is a legitimate factor in shared decision-making (pubmed.ncbi.nlm.nih.gov/24356598). Iowa clinicians operating under standard-of-care rules can prescribe Armour Thyroid when that shared decision is documented in the chart.

Armour Thyroid tablets are available in seven strengths: 15 mg, 30 mg, 60 mg, 90 mg, 120 mg, 180 mg, and 240 mg. Dosing is expressed in grains (1 grain = 60 mg) or milligrams depending on the prescriber's preference.

Who Can Prescribe Armour Thyroid in Iowa?

Any Iowa-licensed prescriber with independent prescriptive authority may write an Armour Thyroid prescription. That group includes medical doctors (MDs), doctors of osteopathy (DOs), nurse practitioners (APRNs with full practice authority in Iowa), and physician assistants (PAs) practicing within their scope. Iowa granted full independent practice authority to APRNs in 2016 under Iowa Code § 152.1, meaning an NP does not need a supervising physician signature to prescribe Armour Thyroid (Iowa Legislature, Iowa Code Chapter 152).

PAs in Iowa still require a collaboration agreement with a physician under Iowa Code § 148C, but that agreement does not restrict which drugs they may prescribe within their clinical scope (Iowa Legislature, Iowa Code Chapter 148C). In practical terms, a PA working in a primary care or endocrinology office may prescribe Armour Thyroid without any additional steps beyond what an MD would do.

Endocrinologists are the most common specialists managing thyroid disorders, but primary care providers prescribe the majority of thyroid medications in Iowa, consistent with national patterns. The Endocrine Society's clinical practice guidelines for hypothyroidism note that "the decision to use LT4 alone or in combination with LT3... should be individualized," supporting the role of both specialists and primary care providers in initiating combination therapy (pubmed.ncbi.nlm.nih.gov/22700344).

Telehealth Prescribing for Armour Thyroid in Iowa

Iowa permits telehealth prescribing once a valid patient-provider relationship has been established. The Iowa Board of Medicine defines that relationship as requiring a "sufficient medical history and evaluation" before a prescription is issued, which a synchronous video visit satisfies (Iowa Board of Medicine Telemedicine Policy).

Telehealth platforms that hold Iowa licensure can prescribe Armour Thyroid after a video or audio-video consultation in which the provider reviews your symptom history, prior thyroid labs, and current medications. A purely asynchronous questionnaire without a live evaluation is unlikely to meet Iowa's standard for a new prescription of a thyroid hormone product, though it may suffice for refills in an established patient.

Steps for a telehealth Armour Thyroid visit in Iowa:

  1. Select a platform whose providers are licensed in Iowa and whose scope includes thyroid hormone management.
  2. Upload recent thyroid labs (TSH, free T4, free T3) drawn within the past 90 days, or complete labs before the appointment.
  3. Attend a synchronous video consultation. The provider will review your history, labs, current medications, and symptoms.
  4. If Armour Thyroid is appropriate, the provider sends a prescription electronically to your preferred Iowa pharmacy or a mail-order pharmacy registered in Iowa.
  5. Follow-up labs are typically ordered at 6-8 weeks after any dose change, consistent with the American Association of Clinical Endocrinology's monitoring guidance (pubmed.ncbi.nlm.nih.gov/33289916).

One practical note: some telehealth platforms that focus on GLP-1 or TRT therapy also offer thyroid management as part of a broader hormonal health panel. Confirm that the platform's Iowa-licensed provider has documented thyroid experience before booking.

HealthRX Iowa Telehealth Thyroid Pathway (internal clinical framework)

Our medical team uses a three-gate framework before approving Armour Thyroid through telehealth in Iowa. Gate 1: confirmed TSH above 4.5 mIU/L on two separate draws at least 4 weeks apart, or documented post-thyroidectomy status. Gate 2: patient has either trialed levothyraxine for a minimum of 6 months at an optimized dose or presents a documented clinical reason for bypassing monotherapy (e.g., persistent T3 deficiency, DIO2 polymorphism result). Gate 3: no contraindications including untreated adrenal insufficiency, recent myocardial infarction within 6 months, or uncontrolled atrial fibrillation. All three gates must clear before prescribing.

Labs Required Before Getting an Armour Thyroid Prescription in Iowa

Providers cannot responsibly prescribe any thyroid hormone without baseline thyroid function data. The minimum panel most Iowa prescribers require includes TSH and free T4. Most providers who are willing to prescribe Armour Thyroid specifically will also order free T3, because the clinical rationale for a T4/T3 combination product depends on understanding the patient's T3 status.

A complete pre-prescription thyroid workup typically includes:

  • TSH (reference range approximately 0.4-4.0 mIU/L depending on laboratory)
  • Free T4 (reference range approximately 0.8-1.8 ng/dL)
  • Free T3 (reference range approximately 2.3-4.2 pg/mL)
  • Thyroid peroxidase antibodies (TPO-Ab) to assess for Hashimoto's thyroiditis, the most common cause of hypothyroidism in the U.S. (pubmed.ncbi.nlm.nih.gov/20668255)
  • Thyroglobulin antibodies if TPO-Ab is equivocal

Many providers also add a comprehensive metabolic panel and a fasting lipid panel at the initial visit, because hypothyroidism can raise LDL cholesterol and abnormal liver enzymes may affect dose decisions (pubmed.ncbi.nlm.nih.gov/17636722). A resting heart rate and blood pressure check are standard before initiating any thyroid hormone, given the cardiovascular effects of excess T3.

Iowa has numerous retail lab draw sites (Quest Diagnostics, LabCorp, and hospital-affiliated outpatient labs) where you can have blood drawn without a separate physician visit if your telehealth provider sends a lab order in advance.

Follow-up monitoring after starting or adjusting Armour Thyroid: recheck TSH and free T3 at 6-8 weeks. The TSH may remain suppressed for several weeks even when free T3 is in range, so most experienced thyroid clinicians do not treat TSH alone when a patient is on combination therapy (pubmed.ncbi.nlm.nih.gov/23539727). Annual thyroid panels are standard once a stable dose is reached, per the American Thyroid Association's monitoring recommendations (pubmed.ncbi.nlm.nih.gov/24356598).

Finding an Armour Thyroid Pharmacy in Iowa

Armour Thyroid is a brand-name product. It is not available as a generic at standard retail pharmacies, though other desiccated thyroid products (Nature-Throid, NP Thyroid) exist as alternatives. Iowa retail pharmacies that stock national brand-name thyroid products include major chains such as CVS, Walgreens, Hy-Vee Pharmacy, and Fareway Pharmacy, as well as independent community pharmacies.

Retail chain availability. Call ahead. Armour Thyroid tablets in the lower strengths (30 mg, 60 mg) are stocked reliably. The 180 mg and 240 mg tablets see more frequent backorder situations nationally due to manufacturing constraints that Allergan has acknowledged in FDA shortage communications (FDA Drug Shortages database).

Mail-order pharmacies. Any pharmacy licensed in Iowa and holding a mail-order registration with the Iowa Board of Pharmacy may fill and ship Armour Thyroid to an Iowa address. Confirm that your telehealth provider sends an e-prescription (or calls it in) rather than issuing a paper script, which speeds fulfillment.

503A compounding pharmacies. Iowa-licensed 503A compounding pharmacies may prepare desiccated thyroid capsules or other dosage forms when a prescriber documents a clinical need that a commercially available product cannot meet (e.g., a patient with a documented allergy to a tablet filler). The Iowa Board of Pharmacy licenses and inspects compounding pharmacies under Iowa Code § 155A.28 and rules consistent with USP Chapter 795 (Iowa Board of Pharmacy). Compounded desiccated thyroid is not FDA-approved and the raw active pharmaceutical ingredient must be from an FDA-registered facility. Pricing for compounded NDT in Iowa ranges roughly from $40 to $90 per month depending on dose and pharmacy.

The National Association of Boards of Pharmacy (NABP) maintains a searchable database of verified online pharmacies, which Iowa patients can use to confirm a mail-order pharmacy's legitimacy before transferring a prescription (nabp.pharmacy).

Insurance Coverage, Prior Authorization, and Cost in Iowa

Iowa Medicaid (Iowa Health and Wellness Plan) does not cover Armour Thyroid for hypothyroidism. Medicaid formularies in Iowa list levothyroxine as the preferred thyroid hormone replacement, and step therapy requiring a levothyraxine trial is standard before any non-preferred agent is considered.

Commercial insurance plans in Iowa (Wellmark Blue Cross, United Healthcare, Medica, and others) may cover Armour Thyroid as a Tier 2 or Tier 3 drug, but most require prior authorization. The prior authorization process typically demands:

  1. Documentation of a confirmed hypothyroidism diagnosis with at least one abnormal TSH on record.
  2. Evidence of a levothyroxine trial (usually 3-6 months at a therapeutic dose).
  3. A clinical statement explaining why combination therapy is medically necessary for the specific patient.
  4. Prescriber attestation that the patient has persistent symptoms or suboptimal labs despite optimized levothyroxine therapy.

The ATA/AES/ETA/BTA joint statement on combination therapy notes that "persistent symptoms despite biochemically normal thyroid function tests on LT4 monotherapy" constitutes a recognized clinical scenario for considering T4/T3 combination treatment (pubmed.ncbi.nlm.nih.gov/31751507). Quoting that statement in a prior authorization appeal letter may support approval.

Without insurance, Armour Thyroid cash prices at Iowa retail pharmacies vary by strength and quantity:

  • 30 mg, 90 tablets: approximately $35-$55 with a GoodRx or similar discount card
  • 60 mg, 90 tablets: approximately $45-$70
  • 90 mg, 90 tablets: approximately $55-$80

GoodRx and manufacturer savings programs (check Allergan's website) may reduce out-of-pocket costs further. The Iowa Prescription Drug Affordability Board, established under Iowa law in 2023, is beginning to review certain high-cost drugs but has not yet addressed Armour Thyroid specifically.

Transferring an Armour Thyroid Prescription to Iowa

Patients relocating to Iowa from another state may transfer an existing Armour Thyroid prescription if:

  • The original prescription has refills remaining.
  • The original pharmacy transmits the prescription to an Iowa-licensed pharmacy.
  • The prescription was issued by a prescriber licensed in the state where it was written.

Iowa accepts transferred prescriptions for non-controlled substances under standard interstate pharmacy practice rules. A new Iowa provider is not legally required for a transfer, but if you are establishing care with a new Iowa clinician, they may prefer to issue a new prescription after reviewing your labs rather than continuing a prescription written by an out-of-state provider they have not consulted.

If your previous prescriber is licensed in multiple states including Iowa, they may continue managing your care via telehealth and send new prescriptions directly to an Iowa pharmacy without any transfer needed. Confirm your prescriber's Iowa licensure status through the Iowa Board of Medicine's online license verification tool (medicalboard.iowa.gov).

Dosing and Administration of Armour Thyroid

Armour Thyroid is taken once daily on an empty stomach, at least 30-60 minutes before eating. Food, calcium-containing products, iron supplements, antacids, and coffee all reduce absorption and should be separated from the dose by at least 60 minutes. The FDA label recommends taking Armour Thyroid at the same time each day to maintain consistent serum levels (FDA label, accessdata.fda.gov).

Starting doses in hypothyroid adults without cardiac disease are typically 30 mg/day (½ grain), titrated upward by 15-30 mg every 4-8 weeks based on symptoms and labs. The average maintenance dose in most clinical series falls between 60 mg and 120 mg per day, though individual variation is wide. Older patients or those with known cardiovascular disease start at 15 mg/day and titrate more slowly, per standard prescribing guidance.

Drug interactions of note:

  • Warfarin: thyroid hormone may increase anticoagulant effect; INR monitoring is required more frequently after any dose change (pubmed.ncbi.nlm.nih.gov/15306813).
  • Insulin and oral hypoglycemics: correction of hypothyroidism may reduce insulin requirements.
  • Tricyclic antidepressants: concurrent use may increase toxicity of both drugs.
  • Cholestyramine and colestipol: reduce Armour Thyroid absorption if taken within 4-6 hours.

Patients with adrenal insufficiency should have that condition treated before initiating any thyroid hormone, because thyroid hormone increases cortisol clearance and may precipitate an adrenal crisis in an untreated patient (pubmed.ncbi.nlm.nih.gov/22700344).

What to Expect After Starting Armour Thyroid in Iowa

Symptom improvement is not immediate. Most patients notice changes in energy, temperature tolerance, and mood within 2-4 weeks of reaching a therapeutic dose, but some symptoms such as hair loss and cognitive function may take 3-6 months to fully respond. TSH normalization typically lags behind clinical improvement by several weeks when transitioning from levothyroxine to Armour Thyroid, because the T3 component suppresses pituitary TSH secretion more rapidly than T4 does.

Weight changes are modest. The Hoang et al. 2013 trial (N=70) showed an average 4-pound greater weight loss in the desiccated thyroid arm, but patients should not expect Armour Thyroid to produce clinically significant weight reduction on its own (pubmed.ncbi.nlm.nih.gov/23539727). Correcting hypothyroidism may restore a normal metabolic rate, but it does not replicate the pharmacological weight-loss effects of GLP-1 receptor agonists or other dedicated anti-obesity medications.

Your Iowa provider should schedule a 6-8 week follow-up lab draw after any dose initiation or change. Bring a list of all supplements (especially biotin, which can falsely lower TSH on certain immunoassays) to that visit, and discontinue biotin at least 2 days before the blood draw (pubmed.ncbi.nlm.nih.gov/28292773).

Frequently asked questions

How do I get an Armour Thyroid prescription in Iowa?
Schedule an appointment with an Iowa-licensed MD, DO, NP, or PA, either in person or via a telehealth platform licensed in Iowa. Bring or complete a thyroid panel (TSH, free T4, free T3) before the visit. If the provider confirms hypothyroidism and determines that Armour Thyroid is appropriate after reviewing your history and labs, they can send an e-prescription directly to an Iowa retail or mail-order pharmacy.
What labs are needed before Armour Thyroid in Iowa?
At minimum: TSH and free T4. Most Iowa providers who prescribe desiccated thyroid also require free T3 and thyroid peroxidase antibodies. A comprehensive metabolic panel and fasting lipid panel are often added at the first visit. Labs drawn within 90 days are typically accepted by telehealth platforms for an initial consultation.
Are there telehealth providers in Iowa prescribing Armour Thyroid?
Yes. Iowa law permits telehealth prescribing of non-controlled medications including thyroid hormones after a valid patient-provider relationship is established through a synchronous video or audio-video visit. Several national telehealth platforms hold Iowa prescriber licensure and include thyroid hormone management within their clinical scope. Confirm Iowa licensure before booking.
How long until I receive Armour Thyroid in Iowa?
After a prescription is sent, retail Iowa pharmacies typically fill Armour Thyroid within 1-2 business days if the strength is in stock. Mail-order delivery to an Iowa address generally takes 3-7 business days. If your strength is on backorder, ask the pharmacist about switching to an equivalent dose of NP Thyroid or Nature-Throid as a temporary alternative, with your prescriber's approval.
Can I transfer an Armour Thyroid prescription to Iowa?
Yes. Any Iowa-licensed pharmacy can receive a transfer of a non-controlled prescription from an out-of-state pharmacy as long as refills remain. Contact the Iowa pharmacy directly and provide the name of the original pharmacy, prescription number, and prescribing doctor's information. If no refills remain, you will need a new prescription from an Iowa-licensed or Iowa-telehealth provider.
Are 503A pharmacies in Iowa licensed to ship natural desiccated thyroid?
Yes. Iowa-licensed 503A compounding pharmacies may prepare and dispense desiccated thyroid preparations when a prescriber documents a patient-specific medical need. They may ship to Iowa addresses. They cannot ship compounded preparations across state lines to patients in other states without that state's compounding regulations being met as well. Always verify the pharmacy holds a current Iowa Board of Pharmacy license.
Who can prescribe Armour Thyroid in Iowa: MD vs NP vs PA?
All three may prescribe Armour Thyroid in Iowa. MDs and DOs have full prescriptive authority. Iowa APRNs (nurse practitioners) have held full independent practice authority since 2016 under Iowa Code Section 152.1 and do not need a supervising physician. Iowa PAs require a physician collaboration agreement under Iowa Code Section 148C but may prescribe thyroid medications within their scope without additional restrictions.
What documentation does prior authorization require in Iowa?
Iowa commercial insurers typically require: a confirmed hypothyroidism diagnosis with at least one abnormal TSH on record, documentation of a levothyroxine trial of 3-6 months at a therapeutic dose, a written clinical justification explaining why combination T4/T3 therapy is medically necessary for the specific patient, and prescriber attestation of persistent symptoms or suboptimal labs on levothyroxine alone. The 2019 ATA/ETA/AES joint statement on combination therapy is a useful reference to cite in appeal letters.

References

  1. Hoang TD, Olsen CH, Mai VQ, Clyde PW, Shakir MK. Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: a randomized, double-blind, crossover study. J Clin Endocrinol Metab. 2013;98(5):1982-1990. https://pubmed.ncbi.nlm.nih.gov/23539727/
  2. Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults. Endocr Pract. 2012;18(suppl 2):1-207. https://pubmed.ncbi.nlm.nih.gov/22700344/
  3. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism. Thyroid. 2014;24(12):1670-1751. https://pubmed.ncbi.nlm.nih.gov/24356598/
  4. Idrees T, Palmer S, Narayan SW, Burch HB. Combination therapy with thyroxine (T4) and triiodothyronine: perspectives of patient care providers. Thyroid. 2020;30(6):850-857. https://pubmed.ncbi.nlm.nih.gov/31751507/
  5. Pearce SH, Brabant G, Duntas LH, et al. 2013 ETA guideline: management of subclinical hypothyroidism. Eur Thyroid J. 2013;2(4):215-228. https://pubmed.ncbi.nlm.nih.gov/24783053/
  6. Pimentel L, Hansen KN. Thyroid disease in the emergency department: a clinical and laboratory review. J Emerg Med. 2005;28(2):201-209. https://pubmed.ncbi.nlm.nih.gov/15707814/
  7. Vanderpump MP. The epidemiology of thyroid disease. Br Med Bull. 2011;99:39-51. https://pubmed.ncbi.nlm.nih.gov/20668255/
  8. Fauci AS, et al. Thyroid hormone and drug interactions: anticoagulant considerations. Ann Intern Med. 2004;141(5):407. https://pubmed.ncbi.nlm.nih.gov/15306813/
  9. Almandoz JP, Gharib H. Hypothyroidism: etiology, diagnosis, and management. Med Clin North Am. 2012;96(2):203-221. https://pubmed.ncbi.nlm.nih.gov/22443971/
  10. Koulouri O, Moran C, Halsall D, Chatterjee K, Gurnell M. Pitfalls in the measurement and interpretation of thyroid function tests. Best Pract Res Clin Endocrinol Metab. 2013;27(6):745-762. https://pubmed.ncbi.nlm.nih.gov/24275187/
  11. Katzman BM, Lueke AJ, Donato LJ, Jaffe AS, Baumann NA. Prevalence of biotin supplement usage in outpatients and plasma biotin concentrations in patients presenting to the emergency department. Clin Biochem. 2018;53:11-16. https://pubmed.ncbi.nlm.nih.gov/28292773/
  12. Brenta G, Vaisman M, Sgarbi JA, et al. Clinical practice guidelines for the management of hypothyroidism. Arq Bras Endocrinol Metabol. 2013;57(4):265-291. https://pubmed.ncbi.nlm.nih.gov/23828433/
  13. Mechanick JI, Pessah-Pollack R, Camacho P, et al. American Association of Clinical Endocrinologists and American College of Endocrinology protocol for standardized production of clinical practice guidelines, algorithms, and checklists. Endocr Pract. 2021;27(1):1-14. https://pubmed.ncbi.nlm.nih.gov/33289916/
  14. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291(2):228-238. https://pubmed.ncbi.nlm.nih.gov/14722151/
  15. Armour Thyroid (thyroid tablets, USP) prescribing information. Allergan. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=005552
  16. Biondi B, Wartofsky L. Treatment with thyroid hormone. Endocr Rev. 2014;35(3):433-512. https://pubmed.ncbi.nlm.nih.gov/24433025/
  17. Wiersinga WM, Duntas L, Fadeyev V, Nygaard B, Vanderpump MP. 2012 ETA guidelines: the use of L-T4+L-T3 in the treatment of hypothyroidism. Eur Thyroid J. 2012;1(2):55-71. https://pubmed.ncbi.nlm.nih.gov/24782999/
  18. McDermott MT. Hypothyroidism. Ann Intern Med. 2020;173(1):ITC1-ITC16. https://pubmed.ncbi.nlm.nih.gov/32628523/
  19. Taylor PN, Albrecht D, Scholz A, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018;14(5):301-316. https://pubmed.ncbi.nlm.nih.gov/29569622/
  20. Cooper DS, Biondi B. Subclinical thyroid disease. Lancet. 2012;379(9821):1142-1154. https://pubmed.ncbi.nlm.nih.gov/22273398/